



# ***Alpa Laboratories Ltd.***

**33/2, Pigdamber A.B. Road - 453 446 Distt. Indore - (M.P.) India**

Phone No. : +91-731- 429 4567 Fax No. : +91-731- 429 4444

Email : mail@alpalabs.in

CIN L85195MP1988PLC004446

31<sup>st</sup> May, 2018

The Manager

Listing Department

**National Stock Exchange of India Limited**

Bandra Kurla Complex, Bandra (East)

Mumbai - 400 051

Dear Sir/ Ma'am,

**Sub.: Clarification in respect of Audited Financial Results for year & quarter ended on 31<sup>st</sup> March, 2018 regarding your mail dated 28<sup>th</sup> May, 2018.**

**Ref.: Symbol: ALPA**

With reference to your mail dated on 28<sup>th</sup> May, 2018 to submit additional information/document in respect of Audited Financial Results for year & quarter ended on 31<sup>st</sup> March, 2018. Please find enclosed herewith following information/documents as required by you:-

1. The Financial result were submitted within 30 minutes from end of board meeting only as meeting started at 4.00 P.M and concluded at 9.50 P.M.
2. Submission of Consolidated Audited Review Report.
3. Submission of Declaration as required under Regulation 33(3)(d) of SEBI (Listing Obligations & Disclosure Requirements), Regulations, 2015.
4. Standalone Reconciliation of Profit and Loss.
5. Standalone Reconciliation of Equity.
6. Consolidated Reconciliation of Profit and Loss.
7. Consolidated Reconciliation of Equity.

You are requested to please consider and take on record the same.


Thanking You,

Yours Truly,

**For ALPA LABORATORIES LIMITED**

*Megha Neema*  
Megha Neema  
Company Secretary

Particulars	Standalone Results					Consolidated Results	
	Quarter Ended			Year Ended		Year Ended	
	Mar-18	Dec-17	Mar-17	Mar-18	Mar-17	Mar-18	Mar-17
	Unaudited			Audited		Audited	
<b>1. Income</b>							
a) Revenue from operations	1,790.78	1,664.06	1,989.21	6,226.82	6,338.08	6,284.68	6,345.15
b) Other Income	47.78	139.99	304.64	451.44	658.40	463.50	513.70
<b>1. Total income from operations (net) (a+b)</b>	<b>1,838.56</b>	<b>1,804.05</b>	<b>2,293.85</b>	<b>6,678.26</b>	<b>6,996.49</b>	<b>6,748.19</b>	<b>6,858.85</b>
<b>2. Expenses</b>							
a) Cost of materials consumed	991.46	911.21	1,054.34	3,304.56	3,419.07	3,304.56	3,419.13
b) Purchases of stock-in-trade	64.89	-	-	226.66	160.27	283.51	160.27
c) Changes in inventories of fin. goods, stock-in-pro. &	59.24	(46.86)	282.24	31.07	52.94	31.07	52.94
d) Employee benefits expense	287.17	250.81	268.37	1,025.56	861.81	1,025.56	867.21
e) Finance costs	15.05	28.47	27.19	107.15	170.95	107.15	170.95
f) Depreciation and amortization expense	32.39	32.64	20.69	112.89	76.08	315.15	278.33
g) Other expenses							
Manufacturing & Operating	85.59	81.35	88.07	357.32	330.14	357.32	330.14
(Stores and spares consumed, power &							
Others	405.63	159.48	210.58	853.32	803.33	855.05	804.51
<b>Total expenses</b>	<b>1,939.43</b>	<b>1,417.10</b>	<b>1,951.48</b>	<b>6,018.53</b>	<b>5,874.58</b>	<b>6,279.36</b>	<b>6,083.47</b>
<b>3. Profit/(Loss) before exceptional items and tax (1-2)</b>	<b>(100.87)</b>	<b>386.95</b>	<b>342.37</b>	<b>659.73</b>	<b>1,121.91</b>	<b>468.83</b>	<b>775.37</b>
<b>4. Exceptional Items</b>	-	-	-	-	211.53	-	211.53
<b>5. Profit/ Loss(-) before tax (3+/-4)</b>	<b>(100.87)</b>	<b>386.95</b>	<b>342.37</b>	<b>659.73</b>	<b>910.38</b>	<b>468.83</b>	<b>563.85</b>
<b>6. Tax (Expenses)/ Benefit</b>							
Current tax	(188.93)	-	293.00	(188.93)	(285.93)	(193.84)	(285.93)
Deferred tax	10.49	-	-	10.49	(25.81)	10.49	(25.81)
<b>7. Profit/ Loss(-) for the period (5+/-6)</b>	<b>(279.31)</b>	<b>386.95</b>	<b>49.37</b>	<b>481.30</b>	<b>598.64</b>	<b>285.48</b>	<b>252.11</b>
<b>8. Other Comprehensive Income</b>							
(i) (a) Items that will not be reclassified to profit or loss	-	-	-	-	-	-	-
(b) Tax expense/(benefit) on items that will not be reclassified to profit or loss	-	-	-	-	-	-	-
(ii) (a) Items that will be reclassified to profit & loss	-	-	-	-	-	-	-
(b) Tax expense/(benefit) on items that will be reclassified to profit or loss	-	-	-	-	-	-	-
<b>Total Other comprehensive (loss)/ income (net of tax)</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>
<b>9. Total comprehensive income for the period ( 16+17)</b>	<b>(279.31)</b>	<b>386.95</b>	<b>49.37</b>	<b>481.30</b>	<b>598.64</b>	<b>285.48</b>	<b>252.11</b>
<b>10. Paid-up equity share capital (Face Value `10 Each)</b>	<b>2,104.06</b>	<b>2,104.06</b>	<b>2,104.06</b>	<b>2,104.06</b>	<b>2,104.06</b>	<b>2,104.06</b>	<b>2,104.06</b>
<b>11. Other equity ( excluding revaluation reserve)</b>	-	-	-	8,223.49	7,742.19	7,654.18	7,368.70
<b>12. Debenture Redemption Reserve</b>	-	-	-	-	-	-	-
<b>13. Basic and Diluted Earnings per share after extraordinary items (not annualized)</b>	<b>(1.33)</b>	<b>1.84</b>	<b>0.23</b>	<b>2.29</b>	<b>2.85</b>	<b>1.36</b>	<b>1.20</b>



For Alpa Laboratories Limited  
*[Signature]*  
 Managing Director



## Annexure IX Statement of Assets and Liabilities

Particulars	Standalone		Consolidated	
	Mar-18 Audited	Mar-17 Audited	Mar-18 Audited	Mar-17 Audited
<b>ASSETS</b>				
<b>Non-current assets</b>				
(a) Property Plant and Equipment	602.58	518.17	602.58	518.17
(b) Capital Work-in-progress	-	-	-	-
(c) Investments Property	-	-	-	419.05
(d) Goodwill	-	-	404.50	506.75
(e) Other Intangible Assets	-	-	-	-
(f) Intangible Assets under development	-	-	-	-
(g) Biological Assets other than bearer Plants	-	-	-	-
(h) Investments in subsidiaries, associates and joint venture	2,370.15	1,555.10	1,291.54	478.54
(b) Financial Assets				
(i) Investment	1,770.79	793.34	1,770.79	793.34
(ii) Trade receivables	-	-	-	-
(iii) Loans	-	-	-	-
(iv) Others	42.20	27.65	42.20	27.65
(i) Deferred tax assets (net)	76.13	65.64	76.13	65.64
(j) Other non-current assets	50.04	43.71	50.04	43.71
<b>Sub-total - Non-current assets</b>	<b>4,911.89</b>	<b>3,003.61</b>	<b>4,237.78</b>	<b>2,952.86</b>
<b>Current Assets</b>				
(a) Inventories	1,372.30	1,303.88	1,372.30	1,303.88
(b) Financial Assets				
(i) Investment	-	-	-	-
(ii) Trade receivables	2,544.16	2,916.08	2,602.02	2,916.08
(iii) Cash and Cash Equivalents	13.50	123.00	19.03	238.33
(iv) Bank Balances other than (iii) above	2,115.06	3,430.00	2,115.06	3,430.00
(v) Short term loans & advances	468.73	1,002.30	705.46	716.34
(vi) Others	72.14	53.78	72.14	53.78
(c) Current Tax Assets (Net)	-	-	-	-
(d) Other current assets	1,365.87	1,198.74	1,232.27	1,065.72
<b>Sub-total - Current assets</b>	<b>7,951.77</b>	<b>10,027.77</b>	<b>8,119.28</b>	<b>9,724.13</b>
<b>TOTAL - ASSETS</b>	<b>12,863.66</b>	<b>13,031.38</b>	<b>12,357.06</b>	<b>12,676.99</b>
<b>EQUITY AND LIABILITIES</b>				
<b>Equity</b>				
(a) Equity Share capital	2,104.06	2,104.06	2,104.06	2,104.06
(b) Other Equity	8,223.49	7,742.19	7,654.18	7,368.70
<b>Sub-total - Equity</b>	<b>10,327.55</b>	<b>9,846.25</b>	<b>9,758.24</b>	<b>9,472.76</b>
<b>Liabilities</b>				
<b>Non-current liabilities</b>				
(a) Financial Liabilities				
(i) Borrowings	18.67	46.90	18.67	46.90
(ii) Trade Payables	-	-	-	-
(iii) Other Financial Liabilities	64.97	62.77	64.97	62.77
(b) Provisions	-	-	-	-
(c) Deferred Tax Liabilities (Net)	-	-	-	-
(d) Other Non-current Liabilities	-	-	-	-
<b>Sub-total - Non-current liabilities</b>	<b>83.64</b>	<b>109.66</b>	<b>83.64</b>	<b>109.66</b>
<b>Current liabilities</b>				
(a) Financial Liabilities				
(i) Borrowings	517.80	1,016.07	517.80	1,016.07
(ii) Trade Payables	1,261.89	1,393.37	1,319.01	1,393.82
(iii) Other Financial Liabilities	113.72	60.57	113.72	60.57
(b) Other Current Liabilities	242.43	328.67	247.79	347.15
(c) Provisions	316.64	276.80	316.87	276.97
(d) Current Tax Liabilities (Net)	-	-	-	-
<b>Sub-total - Current liabilities</b>	<b>2,452.48</b>	<b>3,075.47</b>	<b>2,515.19</b>	<b>3,094.57</b>
<b>TOTAL - EQUITY AND LIABILITIES</b>	<b>12,863.66</b>	<b>13,031.38</b>	<b>12,357.06</b>	<b>12,676.99</b>

## Notes -

1. This statement has been prepared in accordance with the Companies (Indian Accounting Standards) Rules, 2015 (Ind AS) prescribed under Section 133 of the Companies Act, read with rule 3 of the Companies (Indian Accounting Standards) Rules, 2015 and Companies (Indian Accounting Standards) Accounting
  2. The figures for the quarter ended 31/02/2018 and 31/03/2017 represent the balance between the audited figures in respect of the full financial years and those published till the third quarter of the respective financial years.
  3. The Company is operating in the single segment of Drugs & Chemicals.
  4. The Figures of Previous Year/ Periods may have been regrouped/ reclassified wherever necessary.
  5. Application for merger of Norfolk Mercantile Private Limited, Wholly owned subsidiary of Alpa laboratories Limited was filed before NCLT, Mumbai by Norfolk Mercantile Private Limited on 7th December, 2017. The same was approved by the Bench vide Order dated 15th December, 2017. Application was also filed by Alpa laboratories Limited before NCLT Ahmedabad on 15th January, 2018. Against the application an order was issued by the Bench on 2nd February, 2018 for approval of the same in EGM by the Shareholders through Special Resolution. The EGM was conducted on 7th of May, 2018 which approved the same. The Scrutinizer report and the Chairman report was filed on 9th May, 2018. Final petition was filed before the Bench on 15th May, 2018.
- BSE Limited has informed the company through letter dated 8th March, 2018 that a notice has been received by them from one of the advocates on 28th February, 2018 eluding some dispute on title of Equity Shares of Norfolk Mercantile Private Limited. Alpa Laboratories Limited will be filing requisite reply on the same.



For Alpa Laboratories Limited  
*[Signature]*  
 Managing Director





## INDEPENDENT AUDITOR'S REPORT

To the Board of Directors of Alpa Laboratories Limited,


1. We have audited the accompanying Statement of Standalone Financial Results of Alpa Laboratories Limited (the Company), for the year ended March 31, 2018 (the Statement), being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
2. This statement, which is the responsibility of the Company's Management and approved by the Board of Directors, has been compiled from the related standalone financial statements which has been prepared in accordance with the Indian Accounting Standards prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder ('Ind AS') and other accounting principles generally accepted in India. Our responsibility is to express an opinion on the Statement based on our audit of such standalone financial statements.
3. We conducted our audit in accordance with the Standards on Auditing issued by the Institute of Chartered Accountants of India. Those Standards require that we comply with ethical requirements and plan and perform the audit to obtain reasonable assurance about whether the Statement is free from material misstatement.

An audit involves performing procedures to obtain audit evidence about the amounts and the disclosures in the Statement. The procedures selected depend on the auditor's judgement, including the assessment of the risks of material misstatement of the Statement, whether due to fraud or error. In making risk assessments, the auditor considers internal control relevant to the Company's preparation and fair presentation of the Statement in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the Company's internal control. An audit also includes evaluating the appropriateness of the accounting policies used and the reasonableness of the accounting estimates made by the Management, as well as evaluating the overall presentation of the Statement.

We believe that the audit evidence obtained by us is sufficient and appropriate to provide a basis for our audit opinion.

4. In our opinion and to the best of our information and according to the explanations given to us, the statement:
  - (i) is presented in accordance with the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015,
  - (ii) gives a true and fair view in conformity with the aforesaid Indian Accounting Standards and other accounting principles generally accepted in India of the net profit and Total comprehensive income and other financial information of the Company for the year ended March 31, 2018.

For and on behalf of  
**ANURADHA RATNAPARKHI & ASSOCIATES**  
Chartered Accountants  
Firm Registration No.: 0023451C

  
**ANURADHA RATNAPARKHI**  
Proprietor  
Membership No.: 75412



Place: Indore

Date: This 26th day of May, 2018



## INDEPENDENT AUDITOR'S REPORT


To the Board of Directors of Alpa Laboratories Limited,

1. We have audited the accompanying Statement of Consolidated Financial Results of Alpa Laboratories Limited (the parent) and its subsidiaries (the parent and its subsidiaries together referred to as the Group) for the year ended March 31, 2018 (the Statement), being submitted by the parent pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015,
2. This Statement, which is the responsibility of the Parent's Management and approved by the Board of Directors, has been compiled from the related consolidated financial statements which has been prepared in accordance with the Indian Accounting Standards prescribed under Section 133 of the Companies act, 2013, read with relevant rules issued thereunder ("Ind AS") and other accounting principles generally accepted in India. Our responsibility is to express an opinion on the Statement based on our audit of such consolidated financial statements.
3. We conducted our audit in accordance with the standards on Auditing issued by the Institute of Chartered Accountants of India. Those Standards require that we comply with ethical requirements and plan and perform the audit to obtain reasonable assurance about whether the Statement is free from material misstatement.

An audit involves performing procedures to obtain audit evidence about the amounts and the disclosures in the Statement. The procedures selected depend on the auditor's judgement, including the assessment of the risks of material misstatement of the Statement, whether due to fraud or error. In making those risk assessments, the auditor considers internal control relevant to the Parent's preparation and fair presentation of the Statement in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the Parent's internal control. An audit also includes evaluating the appropriateness of the accounting policies used and the reasonableness of the accounting estimates made by the Management, as well as evaluating the overall presentation of the Statement.

4. a. includes the results of the following entities :
    - i) Norfolk Mercantile Private Limited
  - b. is presented in accordance with the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosures Requirements) Regulations, 2015, and
  - c. gives a true and fair view in conformity with the aforesaid Indian Accounting Standards and other accounting principles generally accepted in India of the net profit, total comprehensive income and other financial information of the Group for the year ended March 31, 2018.
5. The statement includes the results for the quarter ended March 31, 2018 being the balancing figure between audited figures in respects of the full financial year and the published year to date figures up to the third quarter of the current financial year, which were subject to limited review.

For and on behalf of  
**ANURADHA RATNAPARKHI & ASSOCIATES**  
Chartered Accountants  
Firm Registration No.: 0023451C

  
**ANURADHA RATNAPARKHI**  
Proprietor  
Membership No.: 75412



Place: Indore

Date: This 26th day of May, 2018





# ***Alpa Laboratories Ltd.***

**33/2, Pigdamber A.B. Road - 453 446 Distt. Indore - (M.P.) India**

**Phone No. : +91-731- 429 4567 Fax No. : +91-731- 429 4444**

**Email : mail@alpalabs.in**

**CIN L85195MP1988PLC004446**

31<sup>st</sup> May, 2018

The Manager

Listing Department

**National Stock Exchange of India Limited**

**Bandra Kurla Complex, Bandra (East)**

**Mumbai - 400 051**

Dear Sir/ Ma'am,

**Sub.: Submission of Declaration as required under Regulation 33(3)(d) of SEBI (Listing Obligations & Disclosure Requirements), Regulations, 2015.**

**Ref.: Symbol: ALPA**

With reference to captioned subject, we hereby submit the following declaration regarding unmodified auditors reports on the Audited Financial Results/ Statements for the year ended 31<sup>st</sup> March, 2018

## **Declaration:**

Based on the Audit Report submitted by Auditors of the Company **M/s. Anuradha Ratnaparkhi & Associates, Chartered Accountants (FRN: 0023451C)**, I the undersigned do hereby declare that in the audit report, accompanying the annual audited financial statements of the Company for the financial year ended 31.03.2018, the auditors does not express any modified opinion(s)/audit qualification(s)/ or other reservation(s) and accordingly the statement on impact of audit qualification is not required to be given.

This declaration is issued in compliance with Regulation 33(3)(d) of SEBI (LODR) Regulations, 2015 as amended by the SEBI (LODR) (Amendment) Regulation, 2016 vide Notification No. SEBI/ LAD-NRO/GN/2016-17/001 dated 25.05.2016 and Circular No. CIR/CFD/CMD/56/2016 dated 27<sup>th</sup> May, 2016.

You are requested to please consider and take on record the same.

Thanking You,

Yours Truly,

**For Alpa Laboratories Ltd.**

*Mahendra*

**Mahendra Singh Chawla**  
Director  
DIN-00362058



# Alpa Laboratories Ltd.

33/2, Pigdamber A.B. Road - 453 446 Distt. Indore - (M.P.) India

Phone No. : +91-731- 429 4567 Fax No. : +91-731- 429 4444

Email : mail@alpalabs.in

CIN L85195MP1988PLC004446

## 1. Standalone Reconciliation of Equity

Standalone Reconciliation of Equity as at 1st April 2016 and as at 31st March 2017.

(Rs. In lacs)

Particular	As at 31 March 2017	As at 1st April 2016
Total equity under Previous GAAP	10,002.02	9,429.97
<b>Adjustment impact Gain /(Loss)</b>		
(a) Net Gain Or Loss on A/c of NAV of Mutual Funds	52.24	(33.00)
(b) Net Gain Or Loss on Preference Shares Through P/L	10.68	(206.12)
( C ) Other	(182.52)	(5.87)
(d) Taxes ( Including Deffered Tax ) on above	(36.17)	86.23
<b>Total IND AS Adjustment</b>	<b>(155.77)</b>	<b>(158.75)</b>
<b>Total Equity as per IND AS</b>	<b>9,846.25</b>	<b>9,271.22</b>

## 2. Consolidated Reconciliation of Equity

Consolidated Reconciliation of Equity as at 1st April 2016 and as at 31st March 2017.

Particular	As at 31 March 2017	As at 1st April 2016
Total equity under Previous GAAP	9,433.61	9,340.53
<b>Adjustment impact Gain /(Loss)</b>		
(a) Net Gain Or Loss on A/c of NAV of Mutual Funds	52.24	(33.00)
( b ) Other	23.08	(5.87)
(d) Taxes ( Including Deffered Tax ) on above	(36.17)	86.23
( e ) Other amortization on a/c of intangible assets		(202.25)
<b>Total IND AS Adjustment</b>	<b>39.15</b>	<b>(154.88)</b>
<b>Total Equity as per IND AS</b>	<b>9,472.76</b>	<b>9,185.64</b>

For Alpa Laboratories Ltd.

*Mahendra*

Mahendra Singh Chawla  
Director  
DIN-00362058



# **Alpa Laboratories Ltd.**

33/2, Pigdamber A.B. Road - 453 446 Distt. Indore - (M.P.) India

Phone No. : +91-731- 429 4567 Fax No. : +91-731- 429 4444

Email : mail@alpalabs.in

CIN L85195MP1988PLC004446

## **3. Reconciliation of Profit After Tax as Reported in Previous GAAP to IND AS ( Standalone) as under.**

( Rs. In lacs)

Particular	Quarter Ended March 2017	Year Ended March 2017
Profit & (Loss) After Tax as reported under Previous GAAP	(10.55)	572.05
<b>Add/(Less) Adjustment under Ind As</b>		
(a) Net Gain Or Loss on A/c of NAV of Mutual Funds	32.87	25.51
(b) Net Gain Or Loss on Preference Shares Through P/L	27.05	27.05
( c) Deferred Tax Adjustment	-	(25.81)
(d) Other Adjustment including change in accounting policy		(0.17)
(e ) Other Comprehensive Income	-	
<b>Profit After tax as per Ind As</b>	<b>49.37</b>	<b>598.64</b>

## **4. Reconciliation of Profit After Tax as Reported in Previous GAAP to IND AS (Consolidated) as under.**

Particular	Year Ended March 2017
Profit & (Loss) After Tax as reported under Previous GAAP	93.08
<b>Add/(Less) Adjustment under Ind As</b>	
(a) Net Gain Or Loss on A/c of NAV of Mutual Funds	25.51
(b) Net Gain Or Loss on Preference Shares Through P/L	27.05
( c) Deferred Tax Adjustment	(25.81)
(d) Other Adjustment including change in accounting policy	132.28
(e ) Other Comprehensive Income	
<b>Profit After tax as per Ind As</b>	<b>252.11</b>

**For Alpa Laboratories Ltd.**

*Mahendra Singh Chawla*

**Mahendra Singh Chawla**  
Director  
DIN-00362058